Pharmafile Logo

Antibody Oligonucleotide Conjugates

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

Eli Lilly HQ

Lilly snags first approval for sarcoma drug Lartruvo

Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

Eli Lilly HQ

Lilly’s president and chief executive John Lechleiter to retire

David Ricks selected to succeed Lechleiter from 1 January 2017

Bristol-Myers Squibb (BMS) building

Opdivo moves closer to head and neck cancer approval

Possible US verdict by November for BMS’ ‘breakthrough’ SCCHN therapy

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links